Blog

In June 2020, the Health Resources and Services Administration (HRSA) reported that net purchasing volume under the 340B program in 2019 was at least $29.9 billion. This accounts for purchases made through wholesalers and excludes direct-from-manufacturer and some specialty distributor purchases – the total volume...

Patient adherence is critical to improving health outcomes and reducing costs to the health care system1. However,  patient adherence remains a significant challenge, particularly in chronic diseases requiring frequent and ongoing pharmaceutical treatment. Health care professionals and health systems recognize this as a significant and...

From mobile devices to wearables and biosensors, digital innovation has led to an exponential increase in the availability of health-related data. While the healthcare market has traditionally been slow to adopt digital innovations (in 2017 14% of US clinician offices still relied on paper medical records) there are now a multitude of ways healthcare companies...

With the recent publication of American Patients First, the Trump administration has provided what it describes as a “blueprint to lower drug prices and reduce patient out-of-pocket costs.” Less a blueprint than a general position document, American Patients First is light on details and heavy...

Determining the right price for a drug involves analyzing multiple variables and carefully articulating value to stakeholders.  Here’s a big-picture view of the process. Pricing pharmaceuticals is not only complex, involving multiple variables and affecting numerous stakeholders, it’s also intensely politically sensitive. Increasing scrutiny of the...